Skip to main content
ASKA Pharmaceutical Holdings CO., Ltd. logo

ASKA Pharmaceutical Holdings CO., Ltd. — Investor Relations & Filings

Ticker · 4886 ISIN · JP3119660003 T Manufacturing
Open in API
Filings indexed 48 across all filing types
Latest filing 2025-06-20 Governance Information
Country JP Japan
Listing T 4886

About ASKA Pharmaceutical Holdings CO., Ltd.

https://www.aska-pharma.co.jp/english/

ASKA Pharmaceutical Holdings Co., Ltd. is a healthcare group engaged in the research, development, manufacturing, and sale of pharmaceuticals. The company specializes in hormone-related medicines, with a primary focus on three therapeutic areas: internal medicine, obstetrics and gynecology, and urology. It is a leading provider of treatments for thyroid disease. The product portfolio includes various hormone preparations, such as the emergency contraceptive pill NORLEVO® and leuprorelin acetate for injection, used in treating conditions like prostate cancer and endometriosis. The group actively pursues the creation of innovative products, including new antibody drugs, through research and development collaborations to meet evolving medical needs.

Recent filings

Filing Released Lang Actions
内部統制報告書－第4期(2024/04/01－2025/03/31)
Governance Information Classification · 100% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly cites the legal basis as "金融商品取引法第24条の４の４第１項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1). This specific filing requirement in Japan mandates the submission of an Internal Control Report, which is a comprehensive annual assessment of internal controls over financial reporting. This aligns perfectly with the scope of an Annual Report or a dedicated internal control disclosure, but given the specific title and legal citation, it is a formal regulatory filing detailing internal control effectiveness, which is often a component or standalone report accompanying the main annual filing (10-K equivalent in the US context, but here it's a specific Japanese disclosure). Since the definitions provided do not have a specific code for the Japanese 'Internal Control Report' (J-SOX), the closest fit that represents a comprehensive, formal annual assessment of financial reporting integrity, distinct from a simple earnings release or audit opinion, is the Annual Report (10-K) category, as this report is intrinsically linked to the annual financial statements. However, looking closely at the provided definitions, there is no direct match for a standalone 'Internal Control Report'. The document is a full report, not an announcement of a report (ruling 2). Given the comprehensive nature and regulatory requirement, it is a core financial disclosure. If we must choose from the list, and recognizing that this is a formal, comprehensive annual disclosure related to financial integrity, it is most closely related to the comprehensive annual reporting structure. Since '10-K' is defined as the 'Official yearly report covering company activity and full financial performance,' and this document details the internal controls underpinning that performance, it is the most appropriate classification among the choices, even if it is a specific Japanese regulatory document type. If 'RNS' (Regulatory Filings) were used as a fallback, it would be too generic. I will classify it as 10-K based on its function as a comprehensive annual control assessment.
2025-06-20 Japanese
有価証券報告書－第4期(2024/04/01－2025/03/31)
Annual Report Classification · 100% confidence The document is identified as a Japanese 'Yuka Shoken Hokokusho' (有価証券報告書), which is the Japanese equivalent of an Annual Report (10-K). The document header explicitly states '有価証券報告書' (Securities Report), cites the Financial Instruments and Exchange Act Article 24, Paragraph 1, and covers a full fiscal year (2024-04-01 to 2025-03-31). It contains comprehensive financial data and corporate disclosures, fitting the definition of an Annual Report. FY 2025
2025-06-20 Japanese
臨時報告書
Capital/Financing Update Classification · 95% confidence The document is explicitly titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is filed with the Kanto Local Finance Bureau. The filing reason states that the company resolved to make an affiliated company a subsidiary through additional stock acquisition, which constitutes a change in specified subsidiary status under Japanese financial regulations (Financial Instruments and Exchange Act). This type of material event disclosure, which is not a standard periodic report (like 10-K or IR) but an immediate disclosure of a significant corporate action (change in control/subsidiary status), typically falls under the general category for timely regulatory announcements in many systems. Given the provided definitions, 'Regulatory Filings' (RNS) is the most appropriate general category for mandatory, non-standard disclosures that don't fit specific categories like M&A (TAR) or Capital Change (CAP), although this is specifically about subsidiary change. Since there is no specific code for 'Change in Subsidiary Status', RNS serves as the best fit for a general, mandatory regulatory filing that is not a standard report or presentation.
2025-02-07 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains Japanese regulatory headers, specifically mentioning "第２四半期報告書" (Second Quarter Report) and referencing the Financial Instruments and Exchange Act ("金融商品取引法"). It confirms the appropriateness of the content for the second quarter period (April 1, 2024, to September 30, 2024). A comprehensive report covering a period shorter than a year (like a semi-annual or quarterly report) corresponds to the Interim / Quarterly Report category (IR). The document appears to be a confirmation or cover page related to the filing of this report, but given its content confirms the contents of the '半期報告書' (Semi-annual Report), it is classified as the report itself or the primary document associated with it, which aligns best with 'IR'. The document length is very short (571 chars), which might suggest an RPA, but the content is a formal confirmation/cover page for a specific regulatory filing (Semi-Annual Report), making 'IR' the most accurate classification for the underlying document type being certified.
2024-11-08 Japanese
半期報告書－第4期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) for ASKA Pharmaceutical Holdings Co., Ltd., covering the period from April 1, 2024, to September 30, 2024. It contains comprehensive financial statements, including the balance sheet, income statement, and cash flow statement, as required by the Financial Instruments and Exchange Act of Japan. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2025
2024-11-08 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is explicitly titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and its submission reason states it is filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act, following the resolutions made at the Annual General Meeting (AGM) held on June 25, 2024. The content details the resolutions passed, specifically regarding the dividend distribution (Item 1), election of a Director (Item 2), and election of an Auditor (Item 3), along with the voting results (approvals, oppositions). This structure—reporting the results of a shareholder meeting—aligns perfectly with the definition of reporting voting results from a general meeting. The closest specific code is DVA (Declaration of Voting Results & Voting Rights Announcements). Although it relates to an AGM, the core content is the voting outcome, not the AGM presentation materials (AGM-R).
2024-06-28 Japanese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.